share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股SEC公告 ·  08/14 16:43
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc. officer Secora Michael is set to sell 15,000 Class A shares on 08/14/2024, with an aggregate market value of $95,251.36. The shares were acquired through stock option exercises on 06/14/2023 and 07/18/2023, with a total of 11,537 and 3,463 shares respectively, both purchased with cash from the issuer. This planned sale follows a history of selling 75,000 shares over the past three months, generating total gross proceeds of $592,415.84. The notice of the upcoming sale was filed on the same date as the planned sale, with the initial plan adoption or instruction given on 03/01/2024.
Recursion Pharmaceuticals, Inc. officer Secora Michael is set to sell 15,000 Class A shares on 08/14/2024, with an aggregate market value of $95,251.36. The shares were acquired through stock option exercises on 06/14/2023 and 07/18/2023, with a total of 11,537 and 3,463 shares respectively, both purchased with cash from the issuer. This planned sale follows a history of selling 75,000 shares over the past three months, generating total gross proceeds of $592,415.84. The notice of the upcoming sale was filed on the same date as the planned sale, with the initial plan adoption or instruction given on 03/01/2024.
Recursion Pharmaceuticals, Inc.的高管Secora Michael計劃在2024年08月14日出售15,000股A類股票,市場價值爲$95,251.36。該股票是通過2023年06月14日和2023年07月18日的股票期權行權獲得的,分別總共購買了11,537股和3,463股,均採用現金從發行方購買。此次計劃銷售是在過去三個月出售75,000股股票的基礎上進行的,總共獲得了$592,415.84的總收入。計劃銷售通知與計劃銷售的同一天提交,初始計劃採用或指令給出於2024年03月01日。
Recursion Pharmaceuticals, Inc.的高管Secora Michael計劃在2024年08月14日出售15,000股A類股票,市場價值爲$95,251.36。該股票是通過2023年06月14日和2023年07月18日的股票期權行權獲得的,分別總共購買了11,537股和3,463股,均採用現金從發行方購買。此次計劃銷售是在過去三個月出售75,000股股票的基礎上進行的,總共獲得了$592,415.84的總收入。計劃銷售通知與計劃銷售的同一天提交,初始計劃採用或指令給出於2024年03月01日。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息